Medivir is a pharmaceutical company focusing on the development of innovative treatments for cancer.
Medivir focuses on cancers of high unmet medical need to provide benefit to patients who so far have had few treatment options.Our projects >
Medivir leverages collaborations with academic and industrial partners in order to bring specialty knowledge, experience and other capabilities to our projects.Partnership >
Medivir publishes prospectus relating to the rights issue – including new financial informationRead more
Resolutions at the extraordinary general meeting in Medivir on 13 January 2021Read more
Medivir presents MIV-818 data at ASCO Gastrointestinal Cancers SymposiumRead more
Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.